



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/826,238	04/16/2004	Alison B. Lukacska	94902.256172	9635
71398	7590	01/22/2010	EXAMINER	
STEPAN KIRCHANSKI VENABLE LLP 2049 CENTURY PARK EAST 21ST FLOOR LOS ANGELES, CA 90067			JACOBI, DONNA A	
ART UNIT	PAPER NUMBER			
1619				
NOTIFICATION DATE	DELIVERY MODE			
01/22/2010	ELECTRONIC			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

SKIRCHANSKI@VENABLE.COM
AMA02@VENABLE.COM
SBP01@VENABLE.COM

Office Action Summary	Application No. 10/826,238	Applicant(s) LUKACSKO, ALISON B.
	Examiner Donna Jagoe	Art Unit 1619

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 05 November 2009.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 45-49 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 45-49 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Claims 45-49 are pending in this application.

Applicants' arguments filed November 5, 2009 have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 45-49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wassenaar U.S. Patent No. 7,060,289 B2 in view of Merck Manual (U).

Wassenaar teaches the method of reducing excessive sweating and minimizing side effects (see abstract) comprising applicant of a topical formulation of glycopyrrolate (an anticholinergic quaternary amine) in a concentration that is from 0.25% to 6% (column 8, lines 29-30). It does not teach the method for killing or inhibiting the growth of microorganisms responsible for fungal infection and non-pathological body malodor. Wassenaar teaches a case study of a patient with excessive sweating of the forehead and groin that resulted in a facial rash and fungal infection. After two weeks of topical application (to the skin surface) the chronic fungal infection of his groin and facial rash had both improved (column 8, lines 32-49).

Merck Manual teaches that athlete's foot, a fungal infection commonly grows in the warm moist areas between the toes.

In holding an invention obvious in view of a combination of references, there must be some suggestion, motivation or teaching in the prior art that would have led a person of ordinary skill in the art to select the references and combine them in the way that would produce the claimed invention. This motivation may flow from the prior art references themselves, the knowledge of one of ordinary skill in the art, or, in some cases, from the nature of the problem to be solved. Here, filtered through the nature of the problem to be solved, the prior art disclosed that moist conditions of the skin leads to fungal infection, and that this problem can be addressed by the application of glycopyrrolate solution in a concentration of 0.25-6%. Thus, inhibition of microorganisms and fungus would result in the application of the glycopyrrolate solution, and in the above case study, a fungus infection could be resolved.

Regarding the concentration of the formulation instantly claimed, the amount of glycopyrrolate of Wassenaar et al. is between 0.25% and 6 % which is encompassed by the instantly claimed 0.0001% to about 20 % or from about 0.05% to about 5%. “[A] prior art reference that discloses a range encompassing a somewhat narrower claimed range is sufficient to establish a *prima facie* case of obviousness.”

In re Peterson, 315 F.3d 1325, 1330, 65 USPQ2d 1379, 1382-83 (Fed. Cir. 2003). See also *In re Harris*, 409 F.3d 1339, 74 USPQ2d 1951 (Fed. Cir. 2005).

It would have been made obvious to one of ordinary skill in art at the time it was made to employ the ACQA, glycopyrrolate, to inhibit growth of microorganisms responsible for fungal infection and malodor motivated by the teaching of Wassenaar, who teaches the method of reducing excessive sweating and minimizing side effects (see abstract) comprising applicant of a topical formulation of glycopyrrolate (an anticholinergic quaternary amine) in a concentration that is from 0.25% to 6% (column 8, lines 29-30) and the teaching of Merck Manual that teaches that athlete's foot fungus is a fungal infection that commonly grows in warm moist areas. Applicant asserts that in the instant invention, Applicant was the first to recognize the anti-fungal properties of this class of compounds. In response, Wassenaar teaches the same antifungal properties of glycopyrrolate, the ultimate species selected in the genus of anticholinergic quaternary amines instantly claimed.

Thus the claims fail to patentably distinguish over the state of the art as represented by the cited references.

Accordingly, for the above reasons, the claims are deemed properly

rejected and none are allowed.

Response to Arguments

Applicant asserts that Wassenaar does not teach a dermatophytic fungus. Applicant's specification defines "dermatophytic fungus" as a chronic fungal infection of the **skin**, hair, nails by dermatophytes. (paragraphs 11-12). Since the groin area is covered in skin, it would be encompassed in Applicant's definition of "dermatophytic fungus". Applicant states that "at the time of the invention ACCQAs were not known to kill or inhibit either bacteria or fungi and that Wassenaar showed that reducing excess sweating resulted in an improvement of a fungal infection of the skin". In response, Wassenaar clearly states in case study No 1 that the patient had excessive forehead and groin sweating resulting in a facial rash and fungal infection. Topical glycopyrrolate was applied in concentrations of 1% and 1.5% whereby the chronic fungal infection improved. When a chronic fungal infection improves, one having ordinary skill in the art would term this improvement as killing or inhibiting the fungal infection. Deeper understanding of the mechanism of action does not render the result and the methods steps employed any different. The art teaches topically applying glycopyrrolate to an area with fungal infection, whereafter the fungal infection improves. Applicant states that one of ordinary skill in the art would understand that the improvement in the fungus infection was attributable to the drying effect of the treatment and does not provide support for this allegation. In response, one having ordinary skill in the art would recognize that fungal infections are not cured by "drying" the area. Fungal infections

are cured by antifungal medications and noted in the Merck Manual reference (see page 2). Further, as stated above, further elucidation of the mechanism of action does not alter the steps and results taught by the art. Applicant asserts that Wassenaar provides no teaching regarding malodor and only teaches a reduction in moisture and "possible reduction in a fungus infection". In response, anyone having an intact olfactory sense would immediately detect malodor in patients having, for example tinea pedis (athletes foot).

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna Jagoe whose telephone number is (571) 272-0576. The examiner can normally be reached on Monday through Friday from 8:00 A.M. - 4:30 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne (Bonnie) Eyer can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/YVONNE L. EYLER/
Supervisory Patent Examiner, Art Unit 1619

Donna Jagoe /D. J./
Examiner
Art Unit 1619

January 6, 2010